Ilyang Pharmaceutical Co.,Ltd Statistics

Total Valuation

Ilyang Pharmaceutical Co.,Ltd has a market cap or net worth of KRW 231.67 billion. The enterprise value is 344.89 billion.

Market Cap	231.67B
Enterprise Value	344.89B

Important Dates

The next estimated earnings date is Wednesday, November 13, 2024.

Earnings Date	Nov 13, 2024
Ex-Dividend Date	n/a

Share Statistics

Ilyang Pharmaceutical Co.,Ltd has 17.97 million shares outstanding. The number of shares has decreased by -0.58% in one year.

Shares Outstanding	17.97M
Shares Change (YoY)	-0.58%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	28.40%
Owned by Institutions (%)	3.87%
Float	12.87M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.63
PB Ratio	1.02
P/FCF Ratio	12.28
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 16.32, with an EV/FCF ratio of 18.28.

EV / Earnings	537.58
EV / Sales	0.94
EV / EBITDA	16.32
EV / EBIT	40.84
EV / FCF	18.28

Financial Position

The company has a current ratio of 0.88, with a Debt / Equity ratio of 0.36.

Current Ratio	0.88
Quick Ratio	0.49
Debt / Equity	0.36
Debt / EBITDA	2.74
Debt / FCF	5.18
Interest Coverage	6.44

Financial Efficiency

Return on equity (ROE) is 1.37% and return on invested capital (ROIC) is 3.95%.

Return on Equity (ROE)	1.37%
Return on Assets (ROA)	3.00%
Return on Capital (ROIC)	3.95%
Revenue Per Employee	562.29M
Profits Per Employee	985,512
Employee Count	651
Asset Turnover	0.76
Inventory Turnover	2.32

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -8.82% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-8.82%
50-Day Moving Average	13,767.40
200-Day Moving Average	13,948.85
Relative Strength Index (RSI)	38.07
Average Volume (20 Days)	25,601

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Ilyang Pharmaceutical Co.,Ltd had revenue of KRW 366.05 billion and earned 641.57 million in profits. Earnings per share was 32.57.

Revenue	366.05B
Gross Profit	194.77B
Operating Income	23.00B
Pretax Income	4.31B
Net Income	641.57M
EBITDA	35.68B
EBIT	23.00B
Earnings Per Share (EPS)	32.57

Full Income Statement

Balance Sheet

The company has 24.62 billion in cash and 97.72 billion in debt, giving a net cash position of -73.09 billion or -4,066.91 per share.

Cash & Cash Equivalents	24.62B
Total Debt	97.72B
Net Cash	-73.09B
Net Cash Per Share	-4,066.91
Equity (Book Value)	268.36B
Book Value Per Share	12,699.06
Working Capital	-24.77B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 31.89 billion and capital expenditures -13.02 billion, giving a free cash flow of 18.87 billion.

Operating Cash Flow	31.89B
Capital Expenditures	-13.02B
Free Cash Flow	18.87B
FCF Per Share	1,049.98

Full Cash Flow Statement

Margins

Gross margin is 53.21%, with operating and profit margins of 6.28% and 0.15%.

Gross Margin	53.21%
Operating Margin	6.28%
Pretax Margin	1.18%
Profit Margin	0.15%
EBITDA Margin	9.75%
EBIT Margin	6.28%
FCF Margin	5.16%

Dividends & Yields

This stock pays an annual dividend of 150.00, which amounts to a dividend yield of 1.16%.

Dividend Per Share	150.00
Dividend Yield	1.16%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	685.90%
Buyback Yield	0.58%
Shareholder Yield	1.74%
Earnings Yield	0.25%
FCF Yield	8.15%

Dividend Details

Stock Splits

The last stock split was on June 26, 2006. It was a forward split with a ratio of 2.

Last Split Date	Jun 26, 2006
Split Type	Forward
Split Ratio	2

Scores

Ilyang Pharmaceutical Co.,Ltd has an Altman Z-Score of 1.68. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.68
Piotroski F-Score	n/a